PNC Financial Services Group Inc. reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 5.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,795 shares of the biopharmaceutical company’s stock after selling 239 shares during the period. PNC Financial Services Group Inc.’s holdings in Intra-Cellular Therapies were worth $272,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in ITCI. Signaturefd LLC increased its stake in Intra-Cellular Therapies by 85.7% in the fourth quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 239 shares during the period. Neo Ivy Capital Management acquired a new position in Intra-Cellular Therapies in the 3rd quarter valued at about $45,000. Cape Investment Advisory Inc. purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at approximately $78,000. Parallel Advisors LLC lifted its position in Intra-Cellular Therapies by 16.3% during the 4th quarter. Parallel Advisors LLC now owns 1,564 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 219 shares during the period. Finally, Assetmark Inc. lifted its position in Intra-Cellular Therapies by 17.8% during the 4th quarter. Assetmark Inc. now owns 2,236 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 338 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, Director Rory B. Riggs sold 4,462 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.57, for a total transaction of $337,193.34. Following the completion of the transaction, the director now directly owns 116,600 shares of the company’s stock, valued at approximately $8,811,462. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Rory B. Riggs sold 4,462 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $75.57, for a total value of $337,193.34. Following the sale, the director now owns 116,600 shares of the company’s stock, valued at approximately $8,811,462. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Nostrand Robert L. Van sold 20,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $75.91, for a total value of $1,518,200.00. Following the transaction, the director now directly owns 9,690 shares of the company’s stock, valued at approximately $735,567.90. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on Intra-Cellular Therapies
Intra-Cellular Therapies Stock Performance
Shares of ITCI stock opened at $67.99 on Tuesday. The stock has a fifty day moving average price of $69.26 and a 200 day moving average price of $69.09. The stock has a market cap of $7.18 billion, a PE ratio of -58.61 and a beta of 1.01. Intra-Cellular Therapies, Inc. has a 1 year low of $45.50 and a 1 year high of $84.89.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. The business had revenue of $144.90 million during the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The business’s revenue was up 52.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.46) EPS. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.51 earnings per share for the current year.
Intra-Cellular Therapies Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
See Also
- Five stocks we like better than Intra-Cellular Therapies
- Most active stocks: Dollar volume vs share volume
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Are Penny Stocks a Good Fit for Your Portfolio?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Investing in Commodities: What Are They? How to Invest in Them
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.